Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 4/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.34 |
| ▸ | CTSD | P07339 | 3/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.31 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5002600 | 0.89 | SLC6A9 (0.37) | NAMPTITGB1ITGA2 | |
| SCHEMBL2417223 | 0.88 | JAK3 (0.35) | JAK3KMT2ABACE1BACE2CTSD | |
| SCHEMBL5003076 | 0.88 | BRD4 (0.34) | ITGB1ITGA2 | |
| SCHEMBL2417225 | 0.88 | JAK3 (0.34) | JAK3KMT2ABACE1BACE2CTSD | |
| SCHEMBL2413180 | 0.85 | HTR6 (0.37) | NAMPTALDH1A1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL2194090 | 0.85 | PTGDR2 (0.33) | NAMPTSMN1; SMN2 | |
| SCHEMBL2415010 | 0.84 | JAK3 (0.36) | JAK3KMT2ABACE1BACE2CTSD | |
| SCHEMBL2409474 | 0.84 | HTR6 (0.36) | PKM | |
| SCHEMBL1580770 | 0.84 | BACE1 (0.38) | JAK3KMT2ABACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4417901 | 0.83 | JAK3 (0.35) | JAK3BACE1BACE2CTSDKAT6A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114917-B1 | PYRROLE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-8933105-B2 | Pyrrole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2364979-A1 | Pyrrole compounds | Takeda Pharmaceutical Company Limited (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262042-A1 | 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker | REN, HRH2, ATP4A | JAK3 2857/4885KMT2A 1066/4885BACE1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.